ADC Therapeutics

ADC Therapeutics touts early Zynlonta results in marginal zone lymphoma, raises $105M through share sale
Fierce Pharma
Mon, 05/6/24 - 05:59 pm
ADC Therapeutics
Zynlonta
marginal zone lymphoma
ADC Discontinues Zynlonta Trial in DLBCL After Seven Deaths
BioSpace
Fri, 07/21/23 - 10:02 am
ADC Therapeutics
Zynlonta
diffuse large B-cell lymphoma
clinical trials
ADC Therapeutics Halts Enrollment of Zynlonta Trial After Seven Patient Deaths
BioSpace
Tue, 07/11/23 - 11:29 pm
ADC Therapeutics
Zynlonta
clinical trials
patient deaths
diffuse large B-cell lymphoma
Biopharma Layoff Tracker 2023: Rain Oncology, Takeda, PTC and more cut staff
BioSpace
Wed, 05/31/23 - 11:15 am
layoffs
Rain Oncology
Takeda
PTC Therapeutics
Affimed
Urovant Sciences
Roche
Novavax
Gossamer Bio
Bristol Myers Squibb
ADC Therapeutics
ADC Therapeutics cuts deal with Sobi to broaden reach of cancer drug
BioPharma Dive
Sun, 07/10/22 - 11:40 pm
ADC Therapeutics
Sobi
Zylonta
cancer
Europe
EHA: ADC preps filings for Hodgkin lymphoma drug after ph2 readout
Pharmaforum
Mon, 06/13/22 - 10:46 am
ADC Therapeutics
antibody-drug conjugate
camidanlumab tesirine
EMA
relapsed or refractory Hodgkins lymphoma
EHA 2022 preview – some good news at last
EP Vantage
Mon, 05/16/22 - 10:14 am
EHA
Caribou Biosciences
CB-010
Gracell
Autolus
Roche
Curocell
ADC Therapeutics
Mustang Bio
ADC Therapeutics strikes a $325M royalty deal to fuel its cancer drug strategy
MedCity News
Fri, 08/27/21 - 10:52 am
ADC Therapeutics
HealthCare Royalty Partners
Zynlonta
large cell B-cell lymphoma
ADC Therapeutics sells off royalty share for lead antibody-drug conjugate in $325M deal
Endpoints
Thu, 08/26/21 - 10:53 am
ADC Therapeutics
Zynlonta
Cami
camidanlumab tesirine
ADC Therapeutics gets the nod from the FDA for its CD19-targeted antibody drug conjugate
Biopharma Reporter
Mon, 04/26/21 - 11:55 am
ADC Therapeutics
Zynlonta
antibody-drug conjugate
FDA
relapsed or refractory diffuse large B-cell lymphoma
FDA sets May date for verdict on ADC’s lymphoma drug Lonca
Pharmaforum
Mon, 11/23/20 - 10:20 am
ADC Therapeutics
Lonca
diffuse large B-cell lymphoma
FDA
priority review
ADC gets priority review for anti-CD19 blood cancer drug
Fierce Biotech
Fri, 11/20/20 - 11:12 am
FDA
ADC Therapeutics
antibody-drug conjugate
Lonca
relapsed or refractory diffuse large B-cell lymphoma
IPO, check: Now, ADC Therapeutics files for lonca approval
Fierce Biotech
Tue, 09/22/20 - 11:03 am
ADC Therapeutics
IPOs
FDA
loncastuximab
diffuse large B-cell lymphoma
What pandemic? Biotech floats break records
EP Vantage
Wed, 07/8/20 - 10:37 am
biotech
IPOs
ADC Therapeutics
Akouos
Applied Molecular Transport
Avidity Biosciences
Ayala Pharmaceuticals
Forma Therapeutics
Fusion Pharmaceuticals
Generation Bio
Hyloris Pharmaceuticals
Lantern Pharma
ORIC Pharmaceuticals
Pliant Therapeutics
PolyPid
Repare Therapeutics
Royalty Pharma
SutroVax
FDA lifts partial hold on ADC, clearing way for a 2021 readout and two potential near-term approvals
Endpoints
Mon, 07/6/20 - 11:01 am
ADC Therapeutics
IPOs
FDA
Cami
Hodgkin's lymphoma
ADC Therapeutics sets IPO terms, to be valued at up to $1 billion
Marketwatch
Fri, 05/15/20 - 11:02 am
ADC Therapeutics
IPOs
cancer
Switzerland
One IPO attempt pulled, a drug on partial hold and a pandemic, but ADC tries again
Fierce Biotech
Wed, 04/29/20 - 10:52 am
ADC Therapeutics
IPOs
COVID-19
loncastuximab
diffuse large B-cell lymphoma
Three Biotechs Raise $320M in IPOs, Two Others Pass on Wall Street
Xconomy
Thu, 10/3/19 - 10:08 pm
IPOs
Viela Bio
Frequency Therapeutics
Aprea Therapeutics
ADC Therapeutics
Monopar Therapeutics
Led by BioNTech, six biotechs line up for October IPOs
Endpoints
Sat, 09/28/19 - 04:38 pm
IPOs
MRNA
melanoma
inebilizumab
NMOSD
blood cancer
solid tumors
BioNTech
ADC Therapeutics
Viela Bio
Frequency Therapeutics
Aprea Therapeutics
Monopar Therapeutics
Does amount matter when it comes to a biotech IPO?
EP Vantage
Wed, 09/25/19 - 11:55 am
IPOs
biotech
NASDAQ
BioNTech
ADC Therapeutics

Pages